United States Type 2 Diabetes Market is expected to reach US$ 124.26 billion by 2033 | Top key players - Novo Nordisk A/S, Sanofi, Pfizer Inc.

Market Size and Forecast:

The Type 2 Diabetes Market Size reached US$ 61.50 billion in 2024 and is expected to reach US$ 124.26 billion by 2033, growing at a CAGR of 8.2% during the forecast period 2025-2033. The Market is growing due to rising prevalence of diabetes, increasing obesity rates, and greater adoption of advanced therapeutic treatments.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/type-2-diabetes-market?sz

The Type 2 Diabetes Market encompasses the global industry involved in the development, production, and commercialization of drugs, devices, and therapies for managing type 2 diabetes. It includes oral medications, insulin, continuous glucose monitoring systems, and other treatment solutions. Market growth is driven by rising diabetes prevalence, lifestyle changes, technological advancements, and increasing awareness of disease management worldwide.

Industry Recent Developments:

United States:

✅ October 2025 - The rapid-acting insulin market in the U.S. is poised for significant growth, driven by rising diabetes prevalence and advancements in insulin delivery systems such as insulin pens and pumps. This market is expected to benefit from personalized diabetes solutions focused on managing post-meal blood sugar surges.

✅ August 2025 - The U.S. diabetes market is expected to surpass $75 billion by 2031, fueled by new drug formulations and integration of AI-powered diabetes management and digital health solutions.

✅ September 2025 - Rising obesity and sedentary lifestyle trends remain major drivers in the U.S., contributing to increasing demand for type 2 diabetes treatments, alongside greater adoption of advanced insulin delivery devices and novel therapeutic pipelines.

Japan:

✅ October 2025 - The Japan antidiabetics market is shifting with aging population and increasing diabetes awareness. There is notable growth in adoption of novel therapies, especially GLP-1 receptor agonists and SGLT2 inhibitors, alongside rising use of digital health tools like continuous glucose monitors and mobile apps for diabetes self-management.

✅ September 2025 - Japan is seeing growth in digital therapeutics for diabetes driven by an aging population and lifestyle changes. Digital solutions including AI-driven platforms and wearable devices help improve remote management and reduce the need for frequent doctor visits.

✅ July 2025 - Technological advancements in diabetes devices, such as continuous glucose monitors and automated insulin delivery systems, along with government initiatives for diabetes prevention and treatment reimbursement, are boosting the Japan diabetes drugs and devices market.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/type-2-diabetes-market?sz

FDA Approvals:

1. Oral Semaglutide (Rybelsus®) for Cardiovascular Risk Reduction
On October 17, 2025, the FDA approved Rybelsus®, the only oral GLP-1 receptor agonist, to reduce the risk of major adverse cardiovascular events (MACE) such as cardiovascular death, heart attack, or stroke in adults with type 2 diabetes at high risk. This approval is based on the SOUL trial, which demonstrated a 14% relative risk reduction in MACE with semaglutide.

2. Ozempic® for Chronic Kidney Disease
In January 2025, the FDA approved Ozempic® (semaglutide) to reduce the risk of kidney disease progression, cardiovascular death, and heart failure in adults with type 2 diabetes and chronic kidney disease. This approval followed a clinical trial involving over 3,500 participants, showing a 24% reduction in kidney disease progression.

3. Kyinsu® (Weekly Diabetes Drug)
In September 2025, the European Medicines Agency's drug review panel recommended approval for Kyinsu®, a weekly diabetes drug, for patients with type 2 diabetes.

Mergers & Acquisitions:

1. Novo Nordisk Acquires Akero Therapeutics
On October 14, 2025, Novo Nordisk announced the acquisition of Akero Therapeutics, a clinical-stage company developing treatments for metabolic diseases, including type 2 diabetes. This acquisition aims to strengthen Novo Nordisk's pipeline in metabolic diseases.

2. Roche's Acquisition of Zealand Pharma's Obesity Drug
In March 2025, Roche secured an agreement worth up to $5.3 billion with Zealand Pharma to acquire the rights for developing and commercializing petrelintide, an obesity drug candidate. This move aims to strengthen Roche's position against market leaders like Novo Nordisk and Eli Lilly in the weight-loss industry.

3. Eli Lilly Acquires Gene-Editing Biotech Verve
In June 2025, Eli Lilly announced a deal to acquire gene-editing start-up Verve Therapeutics for up to $1.3 billion. Verve is developing a CRISPR-based gene therapy targeting the PCSK9 gene, associated with high cholesterol and cardiovascular disease, which could have implications for type 2 diabetes treatment.

Regulatory Approvals:

1. American Diabetes Association (ADA) Standards of Care 2025
The ADA's 2025 Standards of Care include updates such as:
Consideration of continuous glucose monitor (CGM) use for adults with type 2 diabetes on glucose-lowering agents other than insulin.
Guidance on actions to take during medication shortages.
Additional guidance on the use of GLP-1 receptor agonists beyond weight loss for heart and kidney health benefits.

2. International Diabetes Federation (IDF) Global Clinical Practice Recommendations
The IDF's 2025 edition of Global Clinical Practice Recommendations for Managing Type 2 Diabetes provides updated guidelines to improve the lives of people living with diabetes worldwide by equipping healthcare providers with the tools to help them.

Major Key Players:

Novo Nordisk A/S
Eli Lilly and Company.
Sanofi
Pfizer Inc.
Johnson & Johnson Services, Inc.
AstraZeneca.
Boehringer Ingelheim Pharmaceuticals, Inc.
Merck & Co., Inc.
Viatris Inc.
Teva Pharmaceutical Industries Ltd.

Segments Covered in the Type 2 Diabetes Market:

By Drug Type: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors, Alpha-glucosidase Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists), Sodium-glucose Transporter 2 (SGLT2) Inhibitors, Meglitinides, Sulfonylureas, Thiazolidinediones, Biguanides (Metformin), Bile Acid sequestrants (Colesevelam), Amylin Mimetics (Pramlintide).

By Gender: Male, Female.

By Age Group: Up to 19 years, 20 - 65 years, Above 65 years.

By Route of Administration: Oral, Parenteral.

By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Others.

By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

By Region: North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:
◆ How big is the Type 2 Diabetes Market in 2025?
◆ What is the projected growth rate of the Type 2 Diabetes Market through 2033?
◆ Who are the key players in the Type 2 Diabetes Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.